{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:34:13Z","timestamp":1781195653842,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"DOI":"10.7759\/cureus.66520","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:40:52Z","timestamp":1723221652000},"source":"Crossref","is-referenced-by-count":1,"title":["Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial Carcinoma"],"prefix":"10.7759","author":[{"given":"Faisal","family":"Azam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulayel","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Alshangiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rehman","family":"Zar Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedal","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Anwar Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Ibnshamsah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala K","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel). 2020, 8:10.3390\/medsci8010015","journal-title":"Med Sci (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27330","article-title":"A review of the etiology and epidemiology of bladder cancer: all you need to know","volume":"14","author":"Halaseh SA","year":"2022","unstructured":"Halaseh SA, Halaseh S, Alali Y, Ashour ME, Alharayzah MJ. A review of the etiology and epidemiology of bladder cancer: all you need to know. Cureus. 2022, 14:e27330. 10.7759\/cureus.27330","journal-title":"Cureus"},{"key":"ref3","unstructured":"World Cancer Research Fund International - Bladder Cancer Statistics. (2020). Accessed. February 20, 2024: https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100661","article-title":"Non-urothelial and urothelial variants of bladder cancer","volume":"33","author":"Yu EM","year":"2022","unstructured":"Yu EM, Belay S, Li W, Aragon-Ching JB. Non-urothelial and urothelial variants of bladder cancer. Cancer Treat Res Commun. 2022, 33:100661. 10.1016\/j.ctarc.2022.100661","journal-title":"Cancer Treat Res Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1360","article-title":"Diagnostic and therapeutic challenges of rare urogenital cancers: urothelial carcinoma of the renal pelvis, ureters and urethra","volume":"12","author":"Cassell A 3rd","year":"2021","unstructured":"Cassell A 3rd, Manobah B, Willie S. Diagnostic and therapeutic challenges of rare urogenital cancers: urothelial carcinoma of the renal pelvis, ureters and urethra. World J Oncol. 2021, 12:20-7. 10.14740\/wjon1360","journal-title":"World J Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.591","article-title":"Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17)","volume":"112","author":"Choi YJ","year":"2015","unstructured":"Choi YJ, Lee SH, Lee JL, et al.. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). Br J Cancer. 2015, 112:260-5. 10.1038\/bjc.2014.591","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.001","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes","volume":"73","author":"Galsky MD","year":"2018","unstructured":"Galsky MD, Wang H, Hahn NM, et al.. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur Urol. 2018, 73:751-9. 10.1016\/j.eururo.2017.12.001","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602112","article-title":"A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer","volume":"91","author":"Hussain SA","year":"2004","unstructured":"Hussain SA, Stocken DD, Riley P, et al.. A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004, 91:844-9. 10.1038\/sj.bjc.6602112","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.563","article-title":"A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer","volume":"3","author":"Hussain SA","year":"2012","unstructured":"Hussain SA, Palmer DH, Lloyd B, Collins SI, Barton D, Ansari J, James ND. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett. 2012, 3:855-9. 10.3892\/ol.2012.563","journal-title":"Oncol Lett"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1819","article-title":"1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): a multicentre, single-arm phase II trial","volume":"33","author":"Oria G","year":"2022","unstructured":"Oria G, Garc\u00eda-Carbonero I, Esteban-Gonzalez E, et al.. 1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): a multicentre, single-arm phase II trial. Ann Oncol. 2022, 33:1333. 10.1016\/j.annonc.2022.07.1819","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3892\/or.20.1.233","article-title":"A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting","volume":"20","author":"Hussain SA","year":"2008","unstructured":"Hussain SA, Palmer DH, Swinson DE, et al.. A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. Oncol Rep. 2008, 20:233-7. 10.3892\/or.20.1.233","journal-title":"Oncol Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis M","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, et al.. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012, 30:191-9. 10.1200\/JCO.2011.37.3571","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for cisplatin-based chemotherapy","volume":"29","author":"Galsky MD","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, et al.. Treatment of patients with metastatic urothelial cancer \"unfit\" for cisplatin-based chemotherapy. J Clin Oncol. 2011, 29:2432-8. 10.1200\/JCO.2011.34.8433","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"40","author":"Gupta S","year":"2022","unstructured":"Gupta S, Bellmunt J, Plimack ER, et al.. Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC). J Clin Oncol. 2022, 40:4577. 10.1200\/JCO.2022.40.16_suppl.4577","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective","volume":"19","author":"Teoh JY","year":"2022","unstructured":"Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol. 2022, 19:280-94. 10.1038\/s41585-022-00578-1","journal-title":"Nat Rev Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0561","article-title":"Efficacy of split schedule versus conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer","volume":"24","author":"Osterman CK","year":"2019","unstructured":"Osterman CK, Babu DS, Geynisman DM, et al.. Efficacy of split schedule versus conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer. Oncologist. 2019, 24:688-90. 10.1634\/theoncologist.2018-0561","journal-title":"Oncologist"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.02.002","article-title":"Feasibility of cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with diminished renal function","volume":"16","author":"Koshkin VS","year":"2018","unstructured":"Koshkin VS, Barata PC, Rybicki LA, et al.. Feasibility of cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with diminished renal function. Clin Genitourin Cancer. 2018, 16:e879-92. 10.1016\/j.clgc.2018.02.002","journal-title":"Clin Genitourin Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1","article-title":"Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study","volume":"77","author":"Petrioli R","year":"1996","unstructured":"Petrioli R, Frediani B, Manganelli A, et al.. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer. 1996, 77:344-51. 10.1002\/(SICI)1097-0142(19960115)77:2&lt;344::AID-CNCR18&gt;3.0.CO;2-1","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt J","year":"1997","unstructured":"Bellmunt J, Ribas A, Eres N, et al.. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997, 80:1966-72. 10.1002\/(SICI)1097-0142(19971115)80:10&lt;1966::AID-CNCR14&gt;3.0.CO;2-W","journal-title":"Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium","volume":"100","author":"Dreicer R","year":"2004","unstructured":"Dreicer R, Manola J, Roth BJ, et al.. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004, 100:1639-45. 10.1002\/cncr.20123","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti L","year":"2007","unstructured":"Dogliotti L, Carten\u00ec G, Siena S, et al.. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007, 52:134-41. 10.1016\/j.eururo.2006.12.029","journal-title":"Eur Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller RP","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010, 2:2490-518. 10.3390\/toxins2112490","journal-title":"Toxins (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00160810","article-title":"Thoracic malignancies, cisplatin and renal function","volume":"37","author":"Nortier J","year":"2011","unstructured":"Nortier J, Sculier JP. Thoracic malignancies, cisplatin and renal function. Eur Respir J. 2011, 37:760-1. 10.1183\/09031936.00160810","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2015.06.012","article-title":"An integrated view of cisplatin-induced nephrotoxicity and ototoxicity","volume":"237","author":"Karasawa T","year":"2015","unstructured":"Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015, 237:219-27. 10.1016\/j.toxlet.2015.06.012","journal-title":"Toxicol Lett"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000187794","article-title":"Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency","volume":"66","author":"Chatelut E","year":"1994","unstructured":"Chatelut E, Rostaing L, Gualano V, et al.. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron. 1994, 66:157-61. 10.1159\/000187794","journal-title":"Nephron"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733030-00002","article-title":"Clinical pharmacokinetics and dose optimisation of carboplatin","volume":"33","author":"Duffull SB","year":"1997","unstructured":"Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet. 1997, 33:161-83. 10.2165\/00003088-199733030-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref27","article-title":"Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function","volume":"44","author":"Egorin MJ","year":"1984","unstructured":"Egorin MJ, Van Echo DA, Tipping SJ, et al.. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984, 44:5432-8.","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1354","article-title":"Carboplatin pharmacokinetics in a patient receiving hemodialysis","volume":"34","author":"Fong MK","year":"2014","unstructured":"Fong MK, Fetterly GJ Jr, McDougald LJ, Iyer RV. Carboplatin pharmacokinetics in a patient receiving hemodialysis. Pharmacotherapy. 2014, 34:e9-13. 10.1002\/phar.1354","journal-title":"Pharmacotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269751-eligibility-criteria-for-different-platinum-based-chemotherapy-regimens-in-metastatic-urothelial-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:40:58Z","timestamp":1723221658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269751-eligibility-criteria-for-different-platinum-based-chemotherapy-regimens-in-metastatic-urothelial-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.66520","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}